Armata Pharmaceuticals, Inc. — fact timeline

Armata Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026. at the 2026-06-11 meeting.

“Also at the Meeting, our shareholders ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote for such ratification was 29,842,514 shares for, 6,631 shares against, 558 shares abstaining, and 0 shares of broker non-votes.”

Armata Pharmaceuticals, Inc. shareholders approved Approval, on a non-binding advisory basis, of a one-year frequency for future advisory votes on named executive officer compensation. at the 2026-06-11 meeting.

“At the Meeting, our shareholders next approved, on a non-binding advisory basis, a one-year frequency for future advisory votes on the Company’s named executive officer compensation. The vote for such approval was 28,567,809 shares for one year, 2,400 shares for two years, 17,113 shares for three years, 4,914 shares abstaining, and 1,257,467 shares of broker non-votes.”

Armata Pharmaceuticals, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers. at the 2026-06-11 meeting.

“At the Meeting, our shareholders next approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers. The vote for such approval was 28,547,283 shares for, 27,765 shares against, 17,188 shares abstaining, and 1,257,467 shares of broker non-votes.”

Armata Pharmaceuticals, Inc. shareholders approved Election of seven directors to serve for a one-year term at the 2026-06-11 meeting.

“At the Annual Meeting of Shareholders held on June 11, 2026 (the “Meeting”), the shareholders of Armata Pharmaceuticals, Inc. (the “Company”) elected seven members to our board of directors, each for a one-year term expiring at the annual meeting of shareholders in 2027, as follows: Members Number of Shares Voted For Number of Shares Withheld Broker Non- Votes Deborah L. Birx, M.D. 28,349,266 242,970 1,257,467 Daniel B. Gilmer, Ph.D. 28,543,542 48,694 1,257,467 Jules Haimovitz 28,350,690 241,546 1,257,467 Odysseas D. Kostas, M.D. 28,353,918 238,318 1,257,467 Robin C. Kramer 28,537,772 54,464 1,257,467 Joseph M. Patti, Ph.D. 28,544,094 48,142 1,257,467 Sarah Schlesinger, M.D. 28,354,046 238,190 1,257,467”

Armata Pharmaceuticals, Inc. entered into May 2026 Credit Agreement with Innoviva Strategic Opportunities LLC (Innoviva) valued at $25 million (effective 2026-05-12).

“on May 12, 2026, it had entered into, as borrower, a credit and security agreement (the “May 2026 Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company. The May 2026 Credit Agreement provides for a secured term loan facility in an aggregate amount of $25 million”

Armata Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2026.

“On May 13, 2026, the Company announced its financial results for the three months ended March 31, 2026”

Armata Pharmaceuticals, Inc. incurred term loan of $25 million with Innoviva Strategic Opportunities LLC at 14.0% per annum maturing January 11, 2029.

“On May 12, 2026, it had entered into, as borrower, a credit and security agreement (the “May 2026 Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company. The May 2026 Credit Agreement provides for a secured term loan facility in an aggregate amount of $25 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of January 11, 2029.”

Armata Pharmaceuticals, Inc. reported the three months and full fiscal year ended December 31, 2025 results: net income $124.3 million, EPS $(3.42) per share.

“Armata Pharmaceuticals, Inc. announced its financial results for the three months and full fiscal year ended December 31, 2025, in the press release furnished hereto as Exhibit 99.1.”

Armata Pharmaceuticals, Inc. amended Voting Agreement Amendment with Innoviva, Inc. and Innoviva Strategic Opportunities LLC (effective 2026-01-23).

“On January 23, 2026, the Company, Innoviva and Innoviva Sub entered into an amendment (the “Voting Agreement Amendment”) to that certain Second Amended and Restated Voting Agreement, dated February 9, 2022, by and among the Company, Innoviva and Innoviva Sub”

Armata Pharmaceuticals, Inc. amended Warrant Amendment with Innoviva Strategic Opportunities LLC (effective 2026-01-23).

“On January 23, 2026, the Company and Innoviva Sub entered into an amendment (the “Warrant Amendment”) to four outstanding warrant certificates previously issued by the Company to Innoviva Sub.”

Armata Pharmaceuticals, Inc. amended Credit Agreement Amendments with Innoviva Strategic Opportunities LLC (effective 2026-01-23).

“On January 23, 2026, Armata Pharmaceuticals, Inc. (the “Company”) entered into amendments (collectively, the “Credit Agreement Amendments”) to four existing credit agreements, each as previously amended, with Innoviva Strategic Opportunities LLC (“Innoviva Sub”), a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company (“Innoviva”).”

Armata Pharmaceuticals, Inc. entered into Capital on DemandTM Sales Agreement with JonesTrading Institutional Services LLC valued at up to $100,000,000 (effective 2025-12-01).

“On December 1, 2025, Armata Pharmaceuticals, Inc. (the “Company”) entered into a Capital on DemandTM Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC (“Jones”) with respect to an at the market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share (the “Common Stock”), having an aggregate offering price of up to $100,000,000 (the “Placement Shares”) subject to certain conditions, through Jones as sales agent.”

Armata Pharmaceuticals, Inc. incurred term loan of $15 million with Innoviva Strategic Opportunities LLC at 14.0% per annum maturing January 11, 2029.

“The August 2025 Credit Agreement provides for a secured term loan facility in an aggregate amount of $15 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of January 11, 2029.”

Armata Pharmaceuticals, Inc. incurred credit facility of $10 million with Innoviva Strategic Opportunities LLC at 14.0% per annum maturing March 12, 2026.

“The March 2025 Credit Agreement provides for a secured term loan facility in an aggregate amount of $10 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of March 12, 2026.”

Mina Pastagia was terminated as Chief Medical Officer at Armata Pharmaceuticals, Inc..

“On November 13, 2024 (the “Termination Date”), the Company terminated the employment of Mina Pastagia, M.D. (“Dr. Pastagia”), Chief Medical Officer of the Company, effective as of the close of business on the Termination Date.”

Richard Rychlik departed as Vice President, Corporate Controller at Armata Pharmaceuticals, Inc..

“On September 26, 2024, Armata Pharmaceuticals, Inc. (the “ Company ”) disclosed that it had reached an agreement with Richard Rychlik, the Company’s Vice President, Corporate Controller, pursuant to which Mr. Rychlik’s employment would conclude effective as of September 30, 2024.”

Richard Rychlik departed as Vice President, Corporate Controller at Armata Pharmaceuticals, Inc..

“reached an agreement with Richard Rychlik, the Company’s Vice President, Corporate Controller, pursuant to which Mr. Rychlik’s employment will conclude effective as of September 30, 2024.”

David House was appointed as Senior Vice President, Finance at Armata Pharmaceuticals, Inc..

“On July 31, 2024, Armata Pharmaceuticals, Inc. (the “ Company ”) entered into an employment letter agreement (the “ Agreement ”) with David House, pursuant to which he has agreed to serve as the Company’s Senior Vice President, Finance, effective August 16, 2024 (the “ Effective Date ”).”

Armata Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2024.

“On May 7, 2024, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three months ended March 31, 2024, in the press release furnished hereto as Exhibit 99.1.”

Armata Pharmaceuticals, Inc. reported the three months and full fiscal year ended December 31, 2023 results: revenue approximately $1.5 million.

“what we are poised to achieve this year and next,” Dr. Birx concluded. Fourth Quarter 2023 Financial Results Grant Revenue. The Company recognized grant revenue of approximately $1.5 million for the three months ended December 31, 2023, which represents Medical Technology Enterprise Consortium’s share of the costs incurred for the Company’s AP-SA02 program for the”

Armata Pharmaceuticals, Inc. incurred term loan of $35 million with Innoviva Strategic Opportunities LLC at 14.0% per annum maturing June 4, 2025.

“The Credit Agreement provides for a secured term loan facility in an aggregate amount of $35 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of June 4, 2025.”

Armata Pharmaceuticals, Inc. amended Second Amendment to Convertible Credit Agreement with Innoviva.

“and (ii) that certain convertible credit and security agreement (the “Second Amendment to Convertible Credit Agreement” and together with the First Amendment to Credit Agreement, the “Amendments”), dated as of January 10, 2023, by and among the Company, as borrower, Innoviva, as lender, and certain domestic subsidiaries of the Company, as guarantors.”

Armata Pharmaceuticals, Inc. amended First Amendment to Credit Agreement with Innoviva.

“Concurrently with the execution of the Credit Agreement, the Company entered into amendments to (i) that certain credit and security agreement (the “First Amendment to Credit Agreement”), dated as of July 10, 2023, by and among the Company, as borrower, Innoviva, as lender, and certain domestic subsidiaries of the Company, as guarantors”

Armata Pharmaceuticals, Inc. entered into Credit Agreement with Innoviva Strategic Opportunities LLC valued at $35 million (effective 2024-03-04).

“On March 4, 2024, Armata Pharmaceuticals, Inc. (the “Company”) announced in the press release furnished hereto as Exhibit 99.1 that it had entered into, as borrower, a credit and security agreement (the “Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc. (the “Parent”), a principal shareholder of the Company on March 4, 2024.”

Armata Pharmaceuticals, Inc. reported three months ended September 30, 2023 results: revenue grant revenue of approximately $1.2 million.

“through the remainder of the year and into 2024,” Dr. Birx concluded. Third Quarter 2023 Financial Results Grant Revenue. The Company recognized grant revenue of approximately $1.2 million for the three months ended September 30, 2023, which represents Medical Technology Enterprise Consortium (“MTEC”)’s share of the costs incurred for the Company’s AP-SA02 program”

Armata Pharmaceuticals, Inc. shareholders approved Approval of issuance of common stock upon conversion of loan under secured convertible credit and security agreement with Innoviva Strategic Opportunities LLC at the 2023-09-14 meeting.

“Also at the Meeting, our shareholders approved, in accordance with the NYSE American exchange rules, the issuance of our common stock upon conversion, if applicable, of the loan outstanding under our secured convertible credit and security agreement entered into with Innoviva Strategic Opportunities LLC. The vote for such approval was 29,637,787 shares for, 33,901 shares against, 12,671 shares abstaining, and 1,204,286 shares of broker non-votes.”

Armata Pharmaceuticals, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-09-14 meeting.

“Also at the Meeting, our shareholders ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. The vote for such ratification was 30,850,478 shares for, 37,396 shares against, 771 shares abstaining, and 0 shares of broker non-votes.”

Armata Pharmaceuticals, Inc. shareholders approved Non-binding advisory approval of the compensation of the Company's named executive officers at the 2023-09-14 meeting.

“At the Meeting, our shareholders next approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers. The vote for such approval was 29,620,537 shares for, 49,049 shares against, 14,773 shares abstaining, and 1,204,286 shares of broker non-votes.”

Armata Pharmaceuticals, Inc. shareholders approved Election of seven directors to serve for one-year terms expiring at the 2024 annual meeting at the 2023-09-14 meeting.

“At the Annual Meeting of Shareholders held on September 14, 2023 (the “Meeting”), the shareholders of the Company elected seven members to our board of directors, each for a one-year term expiring at the annual meeting of shareholders in 2024, as follows: Members Number of Shares Voted For Number of Shares Withheld Broker Non- Votes Deborah L. Birx, M.D. 29,376,679 307,680 1,204,286 Jules Haimovitz 28,721,661 962,698 1,204,286 Odysseas D. Kostas, M.D. 28,740,184 944,175 1,204,286 Robin C. Kramer 29,478,509 205,850 1,204,286 Joseph M. Patti, Ph. D. 29,478,115 206,244 1,204,286 Todd C. Peterson, Ph. D. 29,483,125 201,234 1,204,286 Sarah Schlesinger, M.D. 28,743,451 940,908 1,204,286”

Richard Rychlik changed role as principal financial officer at Armata Pharmaceuticals, Inc..

“On September 15, 2023, Richard Rychlik, Corporate Controller of Armata Pharmaceuticals, Inc. (“Armata” or the “Company”), was promoted to serve as Armata’s principal financial officer”

Julianne Averill resigned as Chief Financial Officer at Armata Pharmaceuticals, Inc..

“Julianne Averill of Danforth Advisors, LLC, who resigned as Chief Financial Officer on the same day.”

Armata Pharmaceuticals, Inc. reported financial results for the quarter ended June 30, 2023.

“announced its financial results for the quarter ended June 30, 2023”

Dr. Brian Varnum resigned as Chief Executive Officer at Armata Pharmaceuticals, Inc..

“On July 14, 2023, Armata Pharmaceuticals, Inc. (the “Company”) and Dr. Brian Varnum, the Company’s former Chief Executive Officer, entered into a separation and release agreement”

Armata Pharmaceuticals, Inc. amended convertible notes with Innoviva maturing January 10, 2025.

“the parties agreed to, among other things, extend the maturity date from January 10, 2024, to January 10, 2025.”

Armata Pharmaceuticals, Inc. incurred term loan of $25 million with Innoviva Strategic Opportunities LLC at 14.0% per annum maturing January 10, 2025.

“The Credit Agreement provides for a secured term loan facility in an aggregate amount of $25 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of January 10, 2025.”

Armata Pharmaceuticals, Inc. amended First Amendment to Second A&R Voting Agreement with Innoviva and Innoviva, Inc. (effective 2023-07-11).

“In addition, the Company concurrently entered into an amendment (the “First Amendment to Second A&R Voting Agreement”) to its Second Amended and Restated Voting Agreement, dated as of February 9, 2022, by and among the Company, Innoviva and the Parent to extend the expiration date to the earlier of the fifth anniversary of the effective date, or February 9, 2027, and the date of receipt of approval by the U.S. Food and Drug Administration of any of the product candidates of the Company for marketing and commercial distribution.”

Armata Pharmaceuticals, Inc. amended First Amendment to Convertible Credit Agreement with Innoviva (effective 2023-07-11).

“Concurrently with the execution of the Credit Agreement, the Company entered into an amendment to that certain secured convertible credit and security agreement (the “First Amendment to Convertible Credit Agreement”), dated January 10, 2023, by and among the Company, as borrower, Innoviva, as lender, and certain domestic subsidiaries and foreign material subsidiaries of the Company, as guarantors.”

Armata Pharmaceuticals, Inc. entered into Credit Agreement with Innoviva Strategic Opportunities LLC valued at $25 million (effective 2023-07-11).

“On July 11, 2023, Armata Pharmaceuticals, Inc. (the “Company”) announced in the press release furnished hereto as Exhibit 99.1 that it had entered into, as borrower, a credit and security agreement (the “Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc. (the “Parent”), a principal shareholder of the Company on July 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $25 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of January 10, 2025.”

Deborah Birx was appointed as Chief Executive Officer at Armata Pharmaceuticals, Inc..

“On July 11, 2023, the Company announced that the Board of Directors (the “Board”) had appointed Dr. Deborah Birx, 67, to the position of Chief Executive Officer and as a member of the Board”

Brian Varnum was terminated as Chief Executive Officer at Armata Pharmaceuticals, Inc..

“On July 10, 2023, the Company terminated Dr. Brian Varnum as its Chief Executive Officer”

Armata Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2023.

“On May 11, 2023, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023, in the press release furnished hereto as Exhibit 99.1.”

Julianne Averill was appointed as Chief Financial Officer at Armata Pharmaceuticals, Inc..

“On May 4, 2023, the Company’s Board of Directors (the “ Board ”) appointed Julianne Averill to serve, effective as of May 2, 2023, as Chief Financial Officer of the Company and in such capacity, also serve as principal financial officer and principal accounting officer of the Company.”

Erin Butler was terminated as Vice President, Finance and Administration at Armata Pharmaceuticals, Inc..

“On May 1, 2023 (the “ Termination Date ”), in connection with the planned closure of the Company’s San Diego, CA office, Armata Pharmaceuticals, Inc. (the “ Company ”) terminated the employment of Erin Butler, Vice President, Finance and Administration (and principal financial officer and principal accounting officer) of the Company, effective as of close of business on the Termination Date.”

Armata Pharmaceuticals, Inc. reported financial results for full fiscal year ended December 31, 2022.

“Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results”

Armata Pharmaceuticals, Inc. reported three months ended December 31, 2022 results: revenue approximately $1.1 million.

“team is well-positioned for a successful 2023,” concluded Dr. Varnum. Fourth Quarter 2022 Financial Results Grant Revenue. The Company recognized grant revenue of approximately $1.1 million for the three months ended December 31, 2022, which represents Medical Technology Enterprise Consortium (“MTEC”)’s share of the costs incurred for the Company’s AP-SA02 program”

Armata Pharmaceuticals, Inc. incurred term loan of $30 million with Innoviva Strategic Opportunities LLC at 8.0% per annum maturing January 10, 2024.

“The Credit Agreement provides for a secured term loan facility in an aggregate amount of $30 million (the “Loan”) at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024.”

Armata Pharmaceuticals, Inc. entered into Credit Agreement with Innoviva Strategic Opportunities LLC valued at $30 million (effective 2023-01-10).

“On January 10, 2023, Armata Pharmaceuticals, Inc. (the “Company”) entered into, as borrower, a secured convertible credit and security agreement (the “Credit Agreement”) with Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company.”

Armata Pharmaceuticals, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2022 at the 2022-11-16 meeting.

“our shareholders ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022. The vote for such ratification was 31,938,703 shares for, 6,798 shares against, 5,944 shares abstaining, and 0 shares of broker non-votes.”

Armata Pharmaceuticals, Inc. shareholders approved Advisory vote to approve Armata’s 2021 executive compensation at the 2022-11-16 meeting.

“our shareholders next approved on a non-binding advisory basis, Armata’s 2021 executive compensation. The vote for such approval was 31,049,313 shares for, 28,667 shares against, 14,615 shares abstaining, and 858,850 shares of broker non-votes.”

Armata Pharmaceuticals, Inc. shareholders approved Election of seven directors to the board of directors at the 2022-11-16 meeting.

“the shareholders of Armata Pharmaceuticals, Inc. (“Armata”) elected seven members to our board of directors, each for a one-year term expiring at the annual meeting of shareholders in 2023, as follows: Members Number of Shares Voted For Number of Shares Voted Against or Abstained Broker Non- Votes Brian Varnum, Ph. D. 30,859,084 233,511 858,850 Jules Haimovitz 30,207,477 885,118 858,850 Odysseas D. Kostas, M.D. 30,227,120 865,475 858,850 Robin C. Kramer 30,968,830 123,765 858,850 Joseph M. Patti, Ph. D. 30,966,995 125,600 858,850 Todd C. Peterson, Ph. D. 30,966,799 125,796 858,850 Sarah Schlesinger, M.D. 30,862,657 229,938 858,850”